5248242025-04-012025-06-305248242025-04-012025-06-30in-capmkt:OtherExpenses1Member5248242025-04-012025-06-30AuditorDomain1iso4217:INRiso4217:INRxbrli:shares524824BALPHARMANOTLISTEDINE083D01012BAL PHARMA LIMITEDMain BoardEquity2025-04-012026-03-312025-08-112025-07-29INRLakhsQuarterlyFirst quarterSingle segmentPHARMACEUTICLES2025-08-1116:30:002025-08-1117:15:00Declaration of unmodified opinionfalsefalseThe company has not defaulted in repayment of loans during the quarter.2025-04-012025-06-30UnauditedStandalone656351000741100066376200036028500039739000-652180001466830004051900025190000113331000660529000323300003233000000032330000000323300003233000159209000100.20.2000.20.21. The above un audited standalone financial results of the companyhave been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 11.08.2025. <BR> <BR> 2. The standalone financial results has been prepared in accordance with the Companies (Indian Accounting Standards ) Rules, 2015 (IND AS) , 2015, prescribned under section 133 of the Companies Act,2013, tread with relevant rules issued thereunder and other recognized accounting policies to the extend applicable. <BR> <BR> 3. The Company has only one reportable segment namely '' Pharmaceuticals ''. <BR> <BR> 4. The Company has a outstanding recoverability of Rs. 969.37 Lakhs and Rs. 155. 22 Lakhsfrom its subsidiaries Lifezen Healthcare Pvt Ltd and Balance Clinics LLP. The said subsidiaries have incurred losses and have a negative networth. However the management is confident that with infusion of additional funds, introduction of new brands and renewed marketing, internal restructuring, the companies can be revived and amounts be recovered. <BR> <BR> 5. The group has not received any intimation or information with regard to its vendors registration as a Micro, Small and Medium enterprises. Accordingly, the entire dues to vendors has been classified as payable to other tham MSME. <BR> <BR> 6. Golden Drugs Pvt Ltda wholly owned subsidiary of the Company is merged with Bal Pharma Ltd pursuant to NCLT order dated 26.03.2025. <BR> <BR> 7. Previous period figures have been regrouped/ rearranged wherever considered necessary to confirm to the period presentation. Other Expenses113331000UnauditedtrueSSJNB & COMPANYtrue2026-03-31